Radient Pharmaceuticals (RPC) Reports Q1 Loss of $0.13, Revenue Falls Y/Y
Radient Pharmaceuticals (NYSE: RPC) reported Q1 EPS of ($0.13), versus ($0.10) reported last year. Revenue for the quarter came in at $30.66 million, versus $36.85 million reported last year.